This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bears are Losing Control Over Hims & Hers Health (HIMS), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Brokers Suggest Investing in Hims & Hers Health (HIMS): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Hims & Hers Health (HIMS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Hims & Hers Health, Inc. (HIMS) Outpaced the Stock Market Today
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $12.50, signifying a +1.87% move from its prior day's close.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reachead $11.88 at the closing of the latest trading day, reflecting a -0.17% change compared to its last close.
Zacks Investment Ideas feature highlights: Hims & Hers Health, Coinbase Global
by Zacks Equity Research
Hims & Hers Health, Coinbase Global have been highlighted in this Investment Ideas article.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $12.34, moving -0.56% from the previous trading session.
Investing in Growth: 2 Top-Ranked Stocks with Huge Potential
by Ethan Feller
Strong sales growth is a beacon for investors seeking promising companies
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $14.60, denoting a +0.34% change from the preceding trading day.
What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
by Zacks Equity Research
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 70.2% upside potential for Hims & Hers Health, Inc. (HIMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -33.33% and 3.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 50% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 19.61% and 9.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 50% and 7.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
How to Find the Best Cheap Stocks Under $10 to Buy in July
by Benjamin Rains
Today we dive into a pocket of the stock market that many investors like to own as part of diversified portfolios: cheap stocks trading for $10 a share or less. Along with the cheap price tag, the stocks we explore today boast high Zacks Ranks given their improving earnings outlooks.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX